AML is/was the fastest pathway to market. I think it's unlikely they abandon those plans. They only caveat being that with the delays caused by IV formulation there may be a faster pathway to market via cardioprotection.
Would be interesting to know what was discussed with the FDA last November.
General Comments / Chat, page-7156
-
- There are more pages in this discussion • 4,158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.000(0.00%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 100 | 1 |
View Market Depth
| Last trade - 09.52am 26/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable